Liquid Dosage
Protein-based therapeutics are increasingly being developed as new chemical entities in the pharmaceutical and life science industries. Unlike small molecules, which are typically synthesized using chemical processes, most proteins need to be processed in living systems, mostly by recombinant DNA technology. The proteins can then be produced in their functional form (quaternary structure), rather than by microbial biosynthesis (bacteria/yeast), substantially reducing the downstream stages of the process.
As the demand for large-volume products increases, so does the requirement for higher capacity reactors (up to 20,000 L) to realize economies of scale. GEA has responded to the changing needs of biopharmaceutical manufacturers and developed improved technology solutions to optimize both upstream and, with increasing titers, downstream processing, in terms of time and cost efficiency.
Based on its history of innovation and process development, GEA has a thorough working knowledge of therapeutic protein production and has used this competence to design better media and feeding strategies, optimize the fermentation stage and enhance physicochemical conditions during the manufacturing process.
A leading international supplier of integrated process systems, our extensive portfolio of products, technologies and services includes standard and customized fermenters, separators and entire production lines, as well as plant for the production, storage and distribution of clean utilities. Systems for the preparation of media, fluid management, cell cultivation and purification are also part of our global scope of supply.
As a competent manufacturer of complete plant for the life science industries, GEA is a full-service provider of solutions that meet your exact requirements and specifications. From planning, development and installation to qualification and maintenance, our experienced engineers will collaborate with your project team to supply innovative and efficient process solutions for your applications.
Visualizzazione di 4 su 11
Le testate di compressione di GEA sono il cuore pulsante dell'omogeneizzatore poiché attivano il processo di omogeneizzazione pompando il prodotto ad alta pressione per convogliarlo all'interno della valvola di omogeneizzazione.
GEA's thorough understanding of the lyophilization process enables them to supply a comprehensive range of products and services, comprising laboratory equipment, pilot plants for research and small-scale production batches, industrial size pharmaceutical production freeze dryers.
Gli omogeneizzatori da laboratorio GEA, piccoli e compatti, consentono di testare gli effetti dell'omogeneizzazione sul prodotto e valutare quali sono i migliori parametri di processo.
Gli omogeneizzatori industriali GEA sono costituiti da due elementi essenziali: un blocco di compressione che consente di pompare il prodotto ad alta pressione e una valvola di omogeneizzazione, in grado di micronizzare le particelle disperse fino a un ordine di grandezza micrometrica e nanometrica, a seconda delle caratteristiche del prodotto e ...
With the GEA kytero 10, researchers and developers in the biopharmaceutical, food and new food industries now have the latest generation of a powerful accelerator at their disposal.
La vita di Michele Schneider ha avuto una svolta inaspettata quando ha sposato il marito Virlei e i due hanno avviato l'azienda lattiero-casearia Fazenda Inovação Schneider Milk in Brasile. Durante la sua prima esperienza nell'allevamento di bestiame da latte, Michele ha visto crescere rapidamente la sua passione per gli animali e per l'azienda. E così anche il suo carico di lavoro.
GEA aiuta i clienti a testare e sviluppare prodotti e ingredienti alternativi alle uova realizzati con la fermentazione di precisione.